DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie M. Ballantyne, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew J. Budoff, Javed Butler, David Z.I. Cherney, Ralph A. DeFronzo, Stefano Del Prato, Robert H. Eckel, Gerasimos Filippatos, Gregg C. Fonarow, Vivian A. Fonseca, W. Timothy Garvey, Francesco Giorgino, Peter J. Grant, Jennifer B. GreenStephen J. Greene, Per Henrik Groop, George Grunberger, Ania M. Jastreboff, Paul S. Jellinger, Kamlesh Khunti, Samuel Klein, Mikhail N. Kosiborod, Pamela Kushner, Lawrence A. Leiter, Norman E. Lepor, Christos S. Mantzoros, Chantal Mathieu, Christian W. Mende, Erin D. Michos, Javier Morales, Jorge Plutzky, Richard E. Pratley, Kausik K. Ray, Peter Rossing, Naveed Sattar, Peter E.H. Schwarz, Eberhard Standl, P. Gabriel Steg, Lale Tokgözoğlu, Jaakko Tuomilehto, Guillermo E. Umpierrez, Paul Valensi, Matthew R. Weir, John Wilding, Eugene E. Wright

Research output: Contribution to journalReview articlepeer-review

Abstract

The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction–associated steatotic liver disease and metabolism dysfunction–associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes.

Original languageEnglish (US)
Article number155931
JournalMetabolism: clinical and experimental
Volume159
DOIs
StatePublished - Oct 2024

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases'. Together they form a unique fingerprint.

Cite this